Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)
Close on Nov 17, 2026Market cap $290.12MP/E –Yield –
Autolus Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Autolus Therapeutics's price to sales ratio was 2.8× on Nov 11, 2026, against 7.3× a year earlier. Over the last 4 years it ranged from 2.8× to 462.7×, with a median of 183.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.8× | −7.6 |
| 2025 | Dec 31, 2025 | 10.4× | −154.5 |
| 2021 | Jan 29, 2021 | 164.8× | −35.7 |
| 2020 | Dec 31, 2020 | 200.5× | −95.6 |
| 2019 | Dec 31, 2019 | 296.1× | +64.0 |
| 2018 | Oct 31, 2018 | 232.0× | – |
See a number that looks wrong?